SEC 13F Intelligence

Managers / Q3 2019 · view latest →

PFM Health Sciences, LP

CIK 0001442756 · 50 CALIFORNIA STREET, SUITE 2650, SAN FRANCISCO, CA, 94111 · 415-281-1000

Reported Value
$3.4B
Q3 2019
Positions
72
Filings on Record
31
2019–present window
Filed
Nov 14, 2019
original filing

Summary

Pfm Health Sciences, LP reported $3.4B in U.S.-listed holdings across 72 positions for Q3 2019.

Its largest position, Novo Nordisk A S, represents 11.8% of the portfolio.

Compared with Q2 2019, the fund opened 25 new positions and exited 38.

Portfolio Metrics

Turnover
+33.5%
vs prior filed quarter
Top-10 Concentration
+41.8%
share of reported value
Largest Position
+11.8%
Novo Nordisk A S
New / Exited
25 / 38
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $3.8BQ4 ’18Q1 ’19: $4.5BQ2 ’19: $5.3BQ3 ’19: $3.4BQ4 ’19: $2.1BQ4 ’19Q1 ’20: $1.2BQ2 ’20: $1.9BQ3 ’20: $2.2BQ4 ’20: $2.8BQ4 ’20Q1 ’21: $3.3BQ2 ’21: $3.2BQ3 ’21: $3.4BQ4 ’21: $2.9BQ4 ’21Q1 ’22: $2.7BQ2 ’22: $2.6BQ3 ’22: $2.8BQ4 ’22: $2.8BQ4 ’22Q1 ’23: $2.3BQ2 ’23: $2.6BQ3 ’23: $2.1BQ4 ’23: $1.7BQ4 ’23Q1 ’24: $2.1BQ2 ’24: $2.0BQ3 ’24: $1.8BQ4 ’24: $1.6BQ4 ’24Q1 ’25: $1.4BQ2 ’25: $1.2BQ3 ’25: $1.3BQ4 ’25: $1.0BQ4 ’25Q1 ’26: $1.1Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 73.1%Other: 19.6%ETP: 2.6%US DOMESTIC: 2.5%ADR: 2.2%
  • Common Stock · 73.1% · $2.5B
  • Other · 19.6% · $664M
  • ETP · 2.6% · $87M
  • US DOMESTIC · 2.5% · $86M
  • ADR · 2.2% · $73M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NOVO-NORDISK A SNEW+1.13M1.13M+$399M$399M
ALXNALEXION PHARMACEUTICALS INCNEW+1.45M1.45M+$142M$142M
SPDR SERIES TRUSTNEW+1.14M1.14M+$87M$87M
NXP SEMICONDUCTORS N VNEW+709.9K709.9K+$77M$77M
CICIGNA CORP NEWNEW+397.7K397.7K+$60M$60M
NVSNNOVARTIS A GNEW+689.6K689.6K+$60M$60M
PTCTPTC THERAPEUTICS INCNEW+1.65M1.65M+$56M$56M
SG7SAGE THERAPEUTICS INCNEW+373.8K373.8K+$52M$52M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

46 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NOVO-NORDISK A SADR11.79%$399M1.13M
2BMRNBIOMARIN PHARMACEUTICAL INChistory →COM4.28%$145M2.15M
3ALXNALEXION PHARMACEUTICALS INChistory →COM4.18%$142M1.45M
4PENPENUMBRA INChistory →COM4.09%$138M1.03M
5ZBHZIMMER BIOMET HLDGS INChistory →COM4.00%$136M987.8K
6GILDGILEAD SCIENCES INChistory →COM3.45%$117M1.84M
7ARNAEURARENA PHARMACEUTICALS INChistory →COM NEW3.07%$104M2.27M
8IRTCIRHYTHM TECHNOLOGIES INChistory →COM2.37%$80M1.08M
9NXP SEMICONDUCTORS N VCOM2.29%$77M709.9K
10MCHPMICROCHIP TECHNOLOGY INChistory →COM2.28%$77M830.5K
11ALLERGAN PLCSHS2.26%$77M455.6K
12PTCTPTC THERAPEUTICS INCCOM · NOTE 3.000% 8/12.26%$77M21.46M
13IQVIQVIA HLDGS INChistory →COM2.10%$71M477.0K
14WELLCARE HEALTH PLANS INCCOM2.02%$68M263.6K
15BOLDEURAUDENTES THERAPEUTICS INChistory →COM1.92%$65M2.32M
16MYOKEURMYOKARDIA INChistory →COM1.89%$64M1.23M
17DC4DEXCOM INChistory →COM1.89%$64M428.2K
18CICIGNA CORP NEWhistory →COM1.78%$60M397.7K
19NVSNNOVARTIS A Ghistory →SPONSORED ADR1.76%$60M689.6K
20TWLOTWILIO INChistory →CL A1.74%$59M534.9K
21EWEDWARDS LIFESCIENCES CORPhistory →COM1.63%$55M251.8K
22MOHMOLINA HEALTHCARE INChistory →COM1.59%$54M491.8K
23CTLTEURCATALENT INChistory →COM1.56%$53M1.11M
24SG7SAGE THERAPEUTICS INChistory →COM1.55%$52M373.8K
25CRMSALESFORCE COM INChistory →COM1.54%$52M350.4K
26HCAHCA HEALTHCARE INChistory →COM1.48%$50M416.7K
27DERMEURDERMIRA INCNOTE 3.000% 5/1 · COM1.48%$50M34.39M
28INTUINTUIThistory →COM1.41%$48M180.1K
29GDDYGODADDY INChistory →CL A1.41%$48M723.8K
30WDCWESTERN DIGITAL CORPhistory →COM1.40%$47M795.9K
31UNIQURE NVSHS1.35%$46M1.16M
32SYKSTRYKER CORPhistory →COM1.33%$45M207.9K
33PBYIPUMA BIOTECHNOLOGY INChistory →COM1.17%$40M3.69M
34ACORDA THERAPEUTICS INCNOTE 1.750% 6/11.16%$39M49.76M
35AERIEURAERIE PHARMACEUTICALS INChistory →COM1.04%$35M1.83M
36ICON PLCSHS1.03%$35M237.2K
37MSFTMICROSOFT CORPhistory →COM1.03%$35M250.6K
38NVROEURNEVRO CORPhistory →COM1.01%$34M396.3K
39MRTXEURMIRATI THERAPEUTICS INChistory →COM0.99%$34M431.1K
40MKSIMKS INSTRUMENT INChistory →COM0.82%$28M301.6K
41AMDADVANCED MICRO DEVICES INChistory →COM0.76%$26M890.1K
42VVISA INChistory →COM CL A0.68%$23M134.2K
43CSIIEURCARDIOVASCULAR SYS INC DELhistory →COM0.65%$22M465.0K
44COUPEURCOUPA SOFTWARE INChistory →COM0.64%$22M167.3K
45INSPINSPIRE MED SYS INChistory →COM0.63%$21M350.9K
46VYGRVOYAGER THERAPEUTICS INChistory →COM0.63%$21M1.23M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.1B83May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.0B78Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.3B72Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.2B57Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.4B66May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.6B83Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.8B75Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$2.0B78Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.1B87May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.7B65Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$2.1B73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2.6B83Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$2.3B78May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$2.8B89Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$2.8B85Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.6B80Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.7B68May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.9B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$3.4B85Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.2B84Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$3.3B86May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$2.8B85Feb 19, 2021RESTATEMENTchanges · EDGAR ↗
Q3 2020$2.2B77Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.9B76Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.2B61May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.1B61Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$3.4B72Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$5.3B85Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$4.5B90May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$3.8B94Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.